GEORGE HUTTON to Multiple Sclerosis
This is a "connection" page, showing publications GEORGE HUTTON has written about Multiple Sclerosis.
Connection Strength
4.856
-
Immunopathogenesis, Diagnosis, and Treatment of Multiple Sclerosis: A Clinical Update. Neurol Clin. 2023 02; 41(1):87-106.
Score: 0.680
-
Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis. Mult Scler Relat Disord. 2021 Aug; 53:103072.
Score: 0.617
-
The concurrence of multiple sclerosis and glioblastoma. Mult Scler Relat Disord. 2021 May; 50:102877.
Score: 0.606
-
Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis. J Neurol Sci. 2016 Oct 15; 369:51-52.
Score: 0.439
-
Regulatory effects of interferon-? on osteopontin and interleukin-17 expression in multiple sclerosis. J Interferon Cytokine Res. 2010 Oct; 30(10):751-7.
Score: 0.294
-
Role of magnetic resonance imaging and immunotherapy in treating multiple sclerosis. Annu Rev Med. 2005; 56:273-302.
Score: 0.198
-
Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2023 06; 43(6):473-484.
Score: 0.177
-
Health-related quality of life of patients with multiple sclerosis: Analysis of ten years of national data. Mult Scler Relat Disord. 2022 Oct; 66:104019.
Score: 0.166
-
FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS. Mult Scler Relat Disord. 2022 Apr; 60:103703.
Score: 0.162
-
Elsberg syndrome following acute immunosuppressive treatment for multiple sclerosis relapse. Mult Scler Relat Disord. 2022 Feb; 58:103498.
Score: 0.161
-
Prescribing of disease modifying agents in older adults with multiple sclerosis. Mult Scler Relat Disord. 2022 Jan; 57:103308.
Score: 0.158
-
Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021 Sep; 54:103149.
Score: 0.155
-
Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis. Pharmacotherapy. 2021 05; 41(5):440-450.
Score: 0.152
-
Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records. Mult Scler Relat Disord. 2020 Oct; 45:102334.
Score: 0.144
-
Marginal Health Care Expenditure Burden Among U.S. Civilian Noninstitutionalized Individuals with Multiple Sclerosis: 2010-2015. J Manag Care Spec Pharm. 2020 Jun; 26(6):741-749.
Score: 0.144
-
Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data. Res Social Adm Pharm. 2020 Dec; 16(12):1670-1676.
Score: 0.142
-
Histogram analysis of apparent diffusion coefficient and fluid-attenuated inversion recovery in discriminating between enhancing and nonenhancing lesions in multiple sclerosis. Clin Imaging. 2020 Jan; 59(1):13-20.
Score: 0.137
-
Immune thrombocytopenic purpura in a patient with multiple sclerosis treated with natalizumab. Neurology. 2011 Aug 02; 77(5):505-7.
Score: 0.078
-
Autologous HSCT for advanced MS: is the glass half-empty or really half-full? Brain. 2008 Feb; 131(Pt 2):e89; author reply e90.
Score: 0.060
-
The use of magnetic resonance imaging in the diagnosis and long-term management of multiple sclerosis. Neurology. 2004 Dec 14; 63(11 Suppl 5):S3-11.
Score: 0.049
-
Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J Neuroimmunol. 2004 Jul; 152(1-2):126-39.
Score: 0.048
-
Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain. 2004 May; 127(Pt 5):996-1008.
Score: 0.047
-
A comparison of the mechanisms of action of interferon beta and glatiramer acetate in the treatment of multiple sclerosis. Clin Ther. 2002 Dec; 24(12):1998-2021.
Score: 0.043